Eidos Therapeutics Inc (NASDAQ:EIDX) CFO Sells $1,195,000.00 in Stock

Eidos Therapeutics Inc (NASDAQ:EIDX) CFO Christine Siu sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $59.75, for a total value of $1,195,000.00.

Christine Siu also recently made the following trade(s):

  • On Friday, November 22nd, Christine Siu sold 35,000 shares of Eidos Therapeutics stock. The stock was sold at an average price of $57.48, for a total transaction of $2,011,800.00.

Shares of NASDAQ EIDX opened at $59.75 on Friday. The business has a 50-day moving average price of $48.10 and a 200 day moving average price of $39.11. The stock has a market cap of $2.24 billion, a PE ratio of -32.12 and a beta of -0.87. The company has a quick ratio of 17.00, a current ratio of 17.00 and a debt-to-equity ratio of 0.03. Eidos Therapeutics Inc has a 52-week low of $11.15 and a 52-week high of $60.51.

Eidos Therapeutics (NASDAQ:EIDX) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.18 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.48. The firm had revenue of $26.69 million for the quarter. Sell-side analysts anticipate that Eidos Therapeutics Inc will post -1.07 earnings per share for the current year.

Several analysts have recently weighed in on the stock. ValuEngine downgraded shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies increased their target price on shares of Eidos Therapeutics from $55.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th. Barclays downgraded shares of Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $37.00 to $45.00 in a research report on Friday, November 1st. BTIG Research set a $56.00 price target on shares of Eidos Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Finally, Zacks Investment Research raised shares of Eidos Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Eidos Therapeutics currently has a consensus rating of “Buy” and an average price target of $52.00.

Several hedge funds have recently bought and sold shares of the company. Bank of Montreal Can grew its position in shares of Eidos Therapeutics by 151.8% during the second quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock worth $43,000 after acquiring an additional 835 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Eidos Therapeutics in the 2nd quarter valued at $125,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Eidos Therapeutics in the 1st quarter valued at $143,000. Strs Ohio raised its position in Eidos Therapeutics by 457.1% in the 2nd quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after purchasing an additional 9,600 shares during the last quarter. Finally, Swiss National Bank purchased a new stake in Eidos Therapeutics in the 2nd quarter valued at $426,000. 30.46% of the stock is owned by institutional investors and hedge funds.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Recommended Story: What are catch-up contributions?

Insider Buying and Selling by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.